Company profile for Sio Gene Therapies

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At Sio, we operate with a sense of urgency to develop and deliver gene therapies that transform the treatment of serious neurodegenerative diseases. Our aim is to combine cutting-edge science with bold imagination to fill unmet medical needs for patients with one-time therapies that deliver lifelong benefits.Sio is developing AXO-AAV-GM1 and AXO-AAV-GM2 as the first potential treatments for rare and fatal pediatric diseases of...
At Sio, we operate with a sense of urgency to develop and deliver gene therapies that transform the treatment of serious neurodegenerative diseases. Our aim is to combine cutting-edge science with bold imagination to fill unmet medical needs for patients with one-time therapies that deliver lifelong benefits.Sio is developing AXO-AAV-GM1 and AXO-AAV-GM2 as the first potential treatments for rare and fatal pediatric diseases of GM1 gangliosidosis and GM2 gangliosidosis (also known as Tay-Sachs/Sandhoff disease).Sio is developing AXO-Lenti-PD, the only in vivo lentiviral gene therapy in development for Parkinson’s disease.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Eleven Times Square, 33rd Floor New York, NY 10036
Telephone
Telephone
1-877-SIO-GTX1
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com//news-release/2024/02/02/2822755/0/en/Sio-Gene-Therapies-Inc-to-File-for-Dissolution-and-Declare-an-Initial-Liquidating-Distribution-of-0-435-Per-Share.html

GLOBENEWSWIRE
02 Feb 2024

https://www.globenewswire.com/news-release/2023/02/14/2607458/0/en/Sio-Gene-Therapies-Announces-Fiscal-Third-Quarter-2022-Financial-Results.html

GLOBENEWSWIRE
14 Feb 2023
Sio Gene Therapies to dissolve after years of setbacks
Sio Gene Therapies to dissolve after years of setbacks

16 Dec 2022

// Delilah Alvarado BIOPHARMADIVE

https://www.biopharmadive.com/news/sio-gene-therapy-dissolve-shut-down/638873/

Delilah Alvarado BIOPHARMADIVE
16 Dec 2022

https://www.globenewswire.com/news-release/2022/12/14/2574108/0/en/Sio-Gene-Therapies-Inc-Announces-Board-Approval-of-Plan-of-Complete-Liquidation-and-Dissolution.html

GLOBENEWSWIRE
14 Dec 2022

https://www.globenewswire.com/news-release/2022/11/10/2552981/0/en/Sio-Gene-Therapies-Announces-Fiscal-Second-Quarter-2022-Financial-Results.html

GLOBENEWSWIRE
10 Nov 2022

https://www.globenewswire.com/news-release/2022/08/11/2496586/0/en/Sio-Gene-Therapies-Announces-Fiscal-First-Quarter-2022-Financial-Results.html

GLOBENEWSWIRE
11 Aug 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty